JAK2 and cancer: In view of this and the upstream role of JAK1 in the feedback activation of STAT3, the combination of PI3K/AKT/mTOR inhibitors and pan-JAK1/JAK2 inhibitors such as INCB01842442,43 should also be tested in PTEN-deficient cancer cells.